Tubulin-tyrosine ligase-like protein 12(TTLL12): elevated expression in oral squamous cell carcinoma and its clinical prognostic implications Authors: Yu-lu Wang, Yi-run Wang, Lin-sheng Dong, Ya-dong Li Published: 2026 ABSTRACT AbstractBackgroundThe aim of the present study was to investigate the expression of tubulin-tyrosine ligase-like protein 12 (TTLL12) in oral squamous cell carcinoma (OSCC) and to explore its potential associations with clinicopathological characteristics and patient prognosis.MethodsA total of 162 OSCC tissue samples and 30 adjacent normal tissue samples were collected from patients who underwent surgical resection at the First Affiliated Hospital of Chongqing Medical University between May 2014 and December 2018. Paraffin sections were prepared, and TTLL12 expression was detected via immunohistochemistry (IHC). The data were analyzed using SPSS 24.0 software.ResultsImmunohistochemical analysis revealed that TTLL12 expression was significantly higher in OSCC tissues than in normal controls. High TTLL12 expression was significantly correlated with increased tumor size, advanced clinical stage, cervical lymph node metastasis, and risk of new distant metastasis during the follow-up period (P < 0.05). Multivariate Cox regression analysis revealed that TTLL12 expression was an independent prognostic factor for OSCC patient survival (P = 0.035). Moreover, patients with high TTLL12 expression had significantly shorter overall survival (OS) times than those with low TTLL12 expression (P < 0.001).ConclusionsElevated TTLL12 expression is associated with enhanced tumor growth and metastasis in OSCC, leading to poor prognosis. These findings suggest that TTLL12 is a potential biomarker for prognostic assessment in patients with OSCC.Keywords: Oral squamous cell carcinoma, TTLL12, Immunohistochemistry, Prognosis Background Malignant tumors represent a major global health challenge. According to the latest data from the International Agency for Research on Cancer, there were approximately 20 million new cancer cases and nearly 10 million cancer-related deaths worldwide in 2022 [1]. Among various cancers, oral cancer has garnered significant attention because of its high incidence and mortality rates [2], particularly in Asia, where it has high prevalence [3]. Oral squamous cell carcinoma (OSCC) is the most common histological type of oral cancer [4]. While surgical resection remains the primary treatment modality [5], the overall five-year survival rate for OSCC patients remains suboptimal, ranging from 50 to 60% [6]. To improve therapeutic outcomes, researchers are actively seeking biomarkers associated with OSCC development and metastasis, and they are exploring novel treatment strategies. Current evidence indicates that microtubules play a crucial role in cancer progression. Because altered microtubule stability is considered a key factor in tumorigenesis [7], disrupting microtubule dynamics can significantly inhibit cancer cell growth. Consequently, microtubules have emerged as important targets for anticancer therapy, with several microtubule-targeting agents already in clinical use [8]. Microtubules are composed of α- and β-tubulin heterodimers. In addition to their essential role in cell division through the formation of the mitotic spindle [9], microtubules are involved in maintaining cell shape, facilitating cell motility, and enabling intracellular transport [10]. The functionality of tubulin is often regulated by specific posttranslational modifications (PTMs). Enzymes of the tubulin tyrosine ligase-like (TTLL) family mediate these PTMs, influencing tubulin polymerization dynamics and modulating microtubule stability [11]. As the understanding of the TTLL family increases, targeting tubulin modification pathways may offer novel strategies for anticancer therapy [12]. Tubulin tyrosine ligase-like protein 12 (TTLL12) is a member of the TTLL family [13], and it has recently attracted attention in cancer research. Studies have indicated that TTLL12 may function as an oncogene in cancer development [14]. TTLL12 functions as a P™ for α-tubulin [13], and it belongs to a protein family that includes tubulin tyrosine ligase (TTL) and 13 TTLL factors [10]. TTLL12 has been implicated as an oncogene in various malignancies, including prostate cancer, gastric cancer, lung adenocarcinoma, colorectal cancer, and ovarian cancer [15–19]. The aberrant expression of TTLL12 is frequently associated with enhanced cell proliferation and an unfavorable prognosis. Our previous study on head and neck squamous cell carcinoma demonstrated that TTLL12 promotes cancer cell growth by interfering with the binding of nitrotyrosine to tubulin, suggesting its potential as a therapeutic target [20]. Similarly, other studies have indicated that TTLL12 inhibits the linkage of nitrotyrosine to detyrosinated α-tubulin, a process that may further contribute to oncogenesis [21]. On the basis of the literature, we hypothesize that TTLL12 may play a significant role in OSCC pathogenesis and may serve as a potential therapeutic target. However, prospective clinical data directly linking TTLL12 to OSCC are currently lacking, and its expression profile in OSCC tissues remains unclear. Therefore, in this study, 162 OSCC and 30 adjacent normal tissue samples were collected to prepare paraffin sections for immunohistochemical analysis, with the aim of elucidating the expression pattern of TTLL12 in OSCC. Materials and methods Patient characteristics The present study initially included 185 patients with OSCC who underwent surgery in the Department of Oral and Maxillofacial Surgery at the First Affiliated Hospital of Chongqing Medical University between May 2014 and December 2018. The follow-up period ranged from December 2018 to December 2023 and included outpatient reviews, telephone interviews, and medical record examinations. A total of 66 patients died of OSCC (40.7%) during the follow-up period, and there were no non–OSCC deaths. Survival outcomes included overall survival (OS) and cancer-specific survival (CSS). OS was defined as the time from surgery to death due to any cause or the last follow-up, and CSS was defined as the time from surgery to death as a result of oral OSCC or the last follow-up. For patients who were still alive at the end of follow-up, data were censored according to the date of the last follow-up visit. For patients who died from causes other than OSCC in the CSS analysis, data were censored according to the date of death. The cause of death was determined on the basis of hospitalization records and death certificates. Because 23 patients were lost to follow-up, 162 OSCC tissue samples and 30 randomly selected adjacent normal tissue samples (paracancerous normal tissue refers to normal mucosal tissue obtained adjacent to the tumor margin in each patient, with a distance of ≥ 2 cm from the tumor edge, and histologically confirmed to be free of dysplasia and tumor infiltration) were included in the final analysis. Tumor staging was performed according to the 8th edition of the American Joint Committee on Cancer (AJCC) guidelines [22]. The inclusion criteria were primary OSCC confirmed by histopathology and no prior radiotherapy or chemotherapy. The exclusion criteria included distant metastasis at preoperative diagnosis, severe systemic diseases, and concurrent malignancies at other sites. The cohort included 162 patients with a mean age of 61.46 years. Among the included patients, 55 had cervical lymph node metastasis, 107 had no nodal metastasis, and 42 developed distant metastasis during the follow-up period. The detailed clinicopathological data are summarized in Table 1. Table 1TTLL12 expression in OSCC and adjacent normal tissuesTissuenTTLL12Pχ2Low expressionHigh expressionOSCC1628478< 0.00115.103Normal para-cancerous tissues30273 TTLL12 expression in OSCC and adjacent normal tissues Immunohistochemical (IHC) detection of TTLL12 expression IHC staining was performed using the Envision two-step method. Briefly, the paraffin sections were deparaffinized, rehydrated, and subjected to antigen retrieval using citrate buffer. Endogenous peroxidase activity was quenched with hydrogen peroxide. The sections were incubated overnight at 4 °C with a rabbit anti-human TTLL12 polyclonal primary antibody (1:200; ABclonal, A8197), followed by incubation with a goat anti-rabbit IgG secondary antibody (1:200). Diaminobenzidine (DAB) was used for color development, and the sections were counterstained with hematoxylin. Strict negative and positive controls were established throughout the immunohistochemical staining process to validate staining specificity. On the basis of previous literature [23], the positive controls comprised paraffin-embedded tissue sections of human nasopharyngeal carcinoma with high TTLL12, and they underwent the complete staining protocol simultaneously with experimental tissue sections. All positive control sections exhibited characteristic brownish-yellow staining in the cytoplasm and cell membranes, confirming the efficacy of the primary antibodies and the integrity of the experimental system. For the negative controls, PBS buffer (pH 7.4) was used instead of primary antibodies, with all subsequent staining steps identical to those in the experimental group. The negative control sections showed no specific staining and only faint blue background staining from hematoxylin; thus, nonspecific staining interference was excluded. Control staining was performed concurrently for each batch, with only batches meeting the control criteria being included in the final analysis. To ensure consistency in staining, standardized procedures were implemented across three aspects—sample reagent quality control, experimental protocol adherence, and uniform slide evaluation criteria—to guarantee consistent operations at every stage. Five high-power fields (400 ×) were randomly selected from each section and evaluated by two senior pathologists using a double-blind method under microscopy. Disputable results were resolved through consensus discussion. Staining intensity was scored as follows: 0 (negative), 1 (pale yellow), 2 (brownish yellow), and 3 (brown). The percentage of positive cells was scored as follows: 0 (≤ 5%), 1 (> 5% and ≤ 25%), 2 (> 25% and < 50%), and 3 (≥ 50%). The final IHC score was the sum of the intensity and percentage scores. A score ≤ 3 was defined as low expression, and a score > 3 was defined as high expression [24–26]. Statistical analysis Statistical analysis was performed using SPSS 24.0 software. Categorical variables were compared using the chi-square test or Fisher’s exact test, as appropriate. Survival outcomes included OS and CSS. Kaplan‒Meier methods were employed to plot survival curves for OS and CSS, with log-rank tests used to compare intergroup survival differences. Univariate and multivariate Cox proportional hazards regression models were applied to analyze independent risk factors influencing prognosis in OSCC patients. In the CSS analysis, death directly attributable to OSCC was defined as the endpoint event, whereas non–OSCC-related death and loss to follow-up were treated as censored data. Univariate and multivariate Cox proportional hazards models were used to identify independent prognostic factors. Variables with P < 0.05 in univariate analysis were selected for inclusion in multivariate models on the basis of baseline clinical-pathological characteristics without significant collinearity, following clinical consensus screening. Distant metastasis is an endpoint-related event that occurred during the postoperative follow-up period; as it is not a baseline clinical or pathological variable, it was not included in the multivariate Cox regression analysis. A P value < 0.05 was considered to indicate statistical significance. The total sample size of this study was 162 cases, with 66 cancer-specific mortality cases. Only two variables were included in the multivariate Cox model, with an event per variable (EPV) of 66/2 = 33, which was significantly higher than the model stability criterion of “EPV ≥ 10” [27]. The model parameter estimation demonstrated robustness, yielding reliable results. Results Associations between TTLL12 expression and clinicopathological features Among the 162 OSCC tissues, 84 (51.85%) and 78 (48.15%) tissue samples had low and high TTLL12 expression, respectively. Among the 30 adjacent normal tissues, 27 had low expression, and only 3 had high expression. TTLL12 expression was significantly higher in OSCC tissues than in normal mucosa (P < 0.001; Table 1; Fig. 1). In OSCC tissues, TTLL12 staining was localized primarily in the membrane and/or cytoplasm (Fig. 2), which is consistent with previous findings [28]. The Chi-square test revealed that high TTLL12 expression was significantly associated with increased tumor size (P < 0.001), advanced clinical stage (stage I + II vs. III + IV; P < 0.001), cervical lymph node metastasis (P < 0.001), and newly diagnosed distant metastasis during follow-up (P = 0.014). However, no significant correlations were detected between TTLL12 expression and patient age, sex, smoking status, alcohol consumption, tumor location, or pathological differentiation grade (Table 2). These findings suggested that the expression of TTLL12 may play a significant role in tumor development and progression. TTLL12 expression in OSCC and adjacent normal tissues TTLL12 expression in normal mucosal tissues and tumor tissues. A, B TTLL12 expression in normal mucosal tissues. C, D, E, F TTLL12 expression in OSCC tissues. C, D Low TTLL12 expression in OSCC tissue (C × 200; D × 400). E, F High TTLL12 expression in OSCC tissue (E × 200; F × 400) Table 2TTLL12 expression in OSCC and its relationship with clinical pathological featuresClinical pathological featuresnTTLL12χ2PLow expressionHigh expressionSex0.6480.421 Woman573225 Man1055253Age0.5750.448 ≤ 60763739 > 60864739Smoking0.2280.633 No804337 Yes824141Drinking0.1510.698 No934746 Yes693732Tumor location2.0910.719 Cheek472522 Palate1073 Tongue512724 Floor of the mouth301416 Gingiva241113T stage23.561< 0.001 T117107 T2614516 T3662541 T418414Clinical stage20.982 < 0.001 I + II785523 III + IV842955Cervical lymph node metastasis21.362< 0.001 No1077235 Yes551639Pathological differentiation1.3310.249 High differentiation1046044 Mediate and low differentiation582830Distant metastasis*6.0160.014 No1207248 Yes421626Comparisons of categorical variables were performed using the chi-square test or Fisher’s exact test (when the theoretical frequency was < 5)*Distant metastasis: Distant metastasis refers to newly developed distant metastases during follow-up TTLL12 expression in OSCC and its relationship with clinical pathological features Comparisons of categorical variables were performed using the chi-square test or Fisher’s exact test (when the theoretical frequency was < 5) *Distant metastasis: Distant metastasis refers to newly developed distant metastases during follow-up Prognostic value of TTLL12 expression in OSCC Kaplan‒Meier survival analysis revealed that patients with low TTLL12 expression had significantly better OS than those with high TTLL12 expression (P < 0.001; Fig. 3). Similarly, CSS was significantly longer in the low-expression group than in the high-expression group (P < 0.001; Fig. 4). Univariate Cox regression analysis revealed that pathological differentiation grade, clinical stage, cervical lymph node metastasis, and TTLL12 expression level were significant prognostic factors for OS (P < 0.05; Table 3). Subsequent multivariate Cox analysis confirmed that pathological differentiation grade (HR = 2.095; 95% CI: 1.270–3.454; P = 0.004) and high TTLL12 expression (HR = 1.889; 95% CI: 1.045–3.416; P = 0.035) were independent predictors of poor prognosis in patients with OSCC (Table 4). Overall survival (OS) curves of patients with low expression and high expression of TTLL12 in OSCC tissues Cancer-specific survival (CSS) curves of patients with low expression and high expression of TTLL12 in OSCC tissues Table 3Univariate Cox regression analysis of prognostic factors in patients with OSCCVariableHR (95% CI)PSex Woman Man0.894 (0.541 ~ 1.477)0.662Age ≤ 60 > 601.447 (0.883 ~ 2.372)0.142Smoking Yes No1.038 (0.641 ~ 1.683)0.879Drinking No Yes1.178 (0.725 ~ 1.912)0.508Location Cheek10.761 Palate0.817 (0.404 ~ 1.625)0.574 Tongue0.854 (0.414 ~ 1.761)0.668 Floor of the mouth0.794 (0.274 ~ 2.304)0.671 Gingiva0.645 (0.342 ~ 1.215)0.175Clinical stage I + II III + IV1.799 (1.094 ~ 2.960)0.021T stage T110.052 T21.581 (0.543 ~ 4.607)0.401 T32.351 (0.828 ~ 6.674)0.108 T43.694 (1.174 ~ 11.625)0.025Cervical lymph node metastasis No Yes2.119 (1.304 ~ 3.445)0.002Pathological differentiation High differentiation Mediate and low differentiation2.715 (1.670 ~ 4.414)< 0. 001TTLL12 Low expression High expression3.184 (1.880 ~ 5.392)< 0.001Survival analysis was performed using the Kaplan‒Meier method combined with the log-rank test, and a single-factor Cox proportional hazards regression model was employed for prognostic factor analysis Univariate Cox regression analysis of prognostic factors in patients with OSCC Survival analysis was performed using the Kaplan‒Meier method combined with the log-rank test, and a single-factor Cox proportional hazards regression model was employed for prognostic factor analysis Table 4Multivariate Cox regression analysis of prognostic factors in patients with OSCCVariableHR (95% CI)PPathological differentiation High differentiation Mediate and low differentiation2.095 (1.270 ~ 3.454)0.004TTLL12 Low expression High expression1.889 (1.045 ~ 3.416)0.035Survival analysis was performed using the Kaplan‒Meier method combined with the log-rank test, and a multivariate Cox proportional hazards regression model was employed for prognostic factor analysis Multivariate Cox regression analysis of prognostic factors in patients with OSCC Survival analysis was performed using the Kaplan‒Meier method combined with the log-rank test, and a multivariate Cox proportional hazards regression model was employed for prognostic factor analysis Discussion The global incidence of OSCC exceeds 380,000 new cases annually, resulting in approximately 190,000 deaths [1]. The incidence and mortality rates of OSCC are significantly increasing in Asia, contributing substantially to the global burden [29]. OSCC is often diagnosed at an advanced stage because of the absence of early symptoms [30], complicating treatment and leading to poor survival outcomes [31]. Although current treatments include surgery and chemoradiotherapy, the 5-year survival rate remains unsatisfactory, particularly for stage IV patients (53.9%) [32]. Therefore, identifying biomarkers associated with tumor development and metastasis, understanding pathogenic mechanisms, and exploring novel therapeutic targets are critical for improving patient outcomes. Microtubules, which are dynamic polymers of tubulin, are integral to various cellular processes in eukaryotes [33], and they play a significant role in cancer progression [7]. Tubulin requires PTMs, which are mediated by TTLL family enzymes, for optimal function [11]. Aberrant microtubule dynamics can lead to chromosomal instability, a key driver of cancer metastasis [34, 35]. As a member of the TTLL family, TTLL12 has emerged as a potential oncogene, but the role of TTLL12 in OSCC remains underexplored. Given the importance of tubulin PTMs in carcinogenesis, investigating the specific function of TTLL12 in OSCC is warranted. In the present study, IHC analysis of 162 OSCC samples revealed that high TTLL12 expression was significantly associated with advanced T stage, cervical lymph node metastasis, increased risk of new distant metastasis during follow-up, and clinical stage (P < 0.05). These results suggested that TTLL12 may be associated with tumor cell proliferation and invasion. Consistent with the present findings, previous studies have linked elevated TTLL12 expression to metastasis in gastric cancer [16] and have identified it as a key gene in colorectal cancer progression [18]. TTLL12 dysfunction may promote the occurrence and metastasis of various cancers [10]. Overall, these findings suggest that TTLL12 may regulate OSCC cell growth, division, and motility via mediating tubulin PTMs, thereby participating in tumor invasion and metastasis. However, the specific regulatory mechanism needs further in-depth verification. The present study also revealed a significant correlation between TTLL12 expression and OSCC patient survival. Kaplan‒Meier analysis revealed that high TTLL12 expression was associated with shorter overall survival. Cox regression analysis confirmed that TTLL12 was an independent risk factor for poor prognosis, along with pathological differentiation grade. These findings are consistent with those in other cancers. For example, low TTLL12 expression is correlated with better prognosis in prostate cancer [15], and high TTLL12 expression is associated with reduced survival in lung adenocarcinoma [17]. In addition, TTLL12 is an independent risk factor for poor OS in patients with ovarian cancer [19]. These collective data underscore the prognostic value of TTLL12 across multiple malignancies. Although TTLL12 is highly expressed in various cancers and closely associated with prognosis [19], its exact mechanism of action remains incompletely understood and needs further in-depth investigation. In particular, the role and mechanisms of TTLL12 in the growth and invasion of OSCC warrant further research. On the basis of existing research, the oncogenic mechanisms of TTLL12 may involve two components, namely, regulating tubulin posttranslational modifications and modulating nitrotyrosination.​ First, TTLL12 catalyzes tubulin modifications that affect microtubule dynamics, centrosome function, and mitotic spindle integrity. The overexpression of TTLL12 during cancer progression may induce chromosomal instability, promoting tumorigenesis [36]. Second, nitrotyrosination of tubulin is a mechanism that can induce cell death [35]. TTLL12 may compete with nitrotyrosine for binding sites on α-tubulin, thereby inhibiting the cytotoxic effects of nitrotyrosinated tubulin and promoting cancer cell survival [14, 20]. Similarly, Deshpande et al. proposed that TTLL12 protects cancer cells by suppressing nitrotyrosine formation and its linkage to detyrosinated α-tubulin [21]. These findings provide crucial insights into the mechanism of action of TTLL12 in OSCC and establish a theoretical foundation for the development of anticancer therapeutic strategies targeting TTLL12. TTLL12 may serve as a predictive biomarker for disease progression and prognosis in patients with OSCC. However, the present study had several limitations. First, the single-center design and limited sample size may affect the generalizability of the present findings. Future studies should involve larger, multicenter cohorts to validate the expression pattern and clinical significance of TTLL12 in OSCC. Second, the association between TTLL12 expression and clinicopathological parameters was demonstrated, the underlying molecular mechanisms remain to be fully elucidated. Further functional experiments, including proliferation, apoptosis, protein interaction, and transcriptomic analyses, are needed to clarify the precise role of TTLL12 in OSCC cell proliferation and migration. Conclusion High TTLL12 expression in OSCC tissues is closely associated with advanced clinicopathological features and poor prognosis of patients with OSCC. The present findings provide a foundation for understanding the role of TTLL12 in OSCC progression. Future research should focus on elucidating the molecular mechanisms of TTLL12 in OSCC pathogenesis and conducting multicenter studies and functional experiments, which may ultimately contribute to the development of more effective therapeutic strategies and prognostic tools for patients with OSCC. Acknowledgements Not applicable. Abbreviations Oral squamous cell carcinoma Tubulin-tyrosine ligase-like protein 12 Post-translational modifications Tubulin tyrosine ligase-like Tubulin tyrosine ligase American Joint Committee on Cancer Immunohistochemical Diaminobenzidine Overall survival Cancer-specific survival Authors’ contributions WYL was responsible for collecting clinical data, conducting experiments, organizing and statistically analyzing data, and writing the manuscript. WYR assisted in completing immunohistochemical staining and slide analysis. DLS were responsible for collecting clinical specimens and assisting in clinical data collection. LYD guided the project design. Funding Supported by the Natural Science Foundation of Chongqing (CSTB2023NSCQ-MSX0087). Data availability The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate All procedures in this study were conducted in accordance with the ethical principles of the Declaration of Helsinki. The study protocol was approved by the Medical Ethics Committee of Chongqing Medical University (Approval No.: K2023—363) on October 16th, 2023. and written informed consent was obtained from all participants. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.